Archives: Case Studies

Regulatory Due Diligence

Background

A private equity firm pursuing the acquisition of a global medical enterprise engaged Regulatory Compliance Associates® Inc. (RCA) to perform a comprehensive technical due diligence analysis under a highly compressed timeline. The target company operated across North America, Europe, and East Asia, introducing significant complexity and potential risk.

Given the regulated nature of the enterprise, the risks spanned multiple dimensions—including technical, operational, legal, and compliance—with the potential to impact both valuation and deal structure. In addition to identifying critical risks, the private equity firm requested that RCA evaluate the company’s scalability and flag any infrastructure or regulatory barriers that could influence the transaction or provide leverage during negotiations.

Approach

RCA immediately mobilized a cross-functional team of regulatory, technical, and quality subject matter experts. Within 24 hours, appropriate resources were assigned to assess the target company’s regulatory compliance, operational readiness, and quality systems.

Using data room materials and client input, RCA rapidly identified key risk areas and developed a prioritized assessment plan. A detailed due diligence checklist was created to guide the evaluation process during on-site visits.

Over an intensive eight-day period, RCA conducted nineteen facility assessments and a corporate headquarters review. Throughout the engagement, the client received daily updates that were incorporated into active deal negotiations.

Result

RCA delivered a comprehensive due diligence report covering regulatory, technical, and quality-related findings, along with quantified assessments of health and safety liabilities, infrastructure gaps, and remediation costs. Expansion capabilities and potential structural limitations were also mapped, allowing the client to make fully informed decisions.

The findings provided the private equity firm with powerful insights that supported a successful negotiation and enabled them to adjust the purchase price to account for uncovered risks. RCA’s real-time guidance and expert recommendations ensured the client had a strategic advantage throughout the transaction process.

Pharmaceutical Development and Regulatory Submission

Client Challenge

A global pharmaceutical manufacturer encountered a critical supply chain disruption when their API supplier unexpectedly terminated the partnership. As a result, a substantial quantity of active pharmaceutical ingredient (API), though properly stored and controlled, was at risk of expiration due to a lack of FDA approval. The situation was further complicated by uncertainties regarding the completeness of the supplier’s Drug Master File (DMF), the availability of essential development and stability data, and the absence of a qualified replacement supplier.

RCA Approach

Regulatory Compliance Associates® Inc. (RCA) was engaged to resolve the issue and safeguard the client’s valuable API inventory. RCA initiated a comprehensive retesting protocol, confirming that the API had remained stable and within specification under controlled storage conditions. To reestablish supply continuity, RCA identified and qualified a new supplier, while deploying analytical chemists and development scientists to address critical manufacturing challenges—including issues with particle size and crystal drying in the new production process.

Concurrently, RCA’s regulatory experts located and thoroughly evaluated the previous supplier’s Drug Master File (DMF), uncovering essential development and stability data. Leveraging this information, RCA assisted the client in compiling and submitting a CBE-30 supplement to the FDA. This strategic submission enabled the client to gain FDA approval for continued use of the existing API, despite the supplier transition.

Result

The FDA found no deficiencies in the submission, allowing the pharmaceutical company to proceed with the use of the original API—realizing cost savings estimated in the eight-figure range. In parallel, RCA updated and streamlined the company’s Common Technical Document (CTD) framework, delivering structured templates to support ongoing lifecycle management of the product. This comprehensive effort not only averted a costly API replacement but also safeguarded a critical revenue stream and reinforced the long-term stability and compliance of the manufacturing process.

Strategy for Pharmaceutical Submission

Background

A major manufacturer of intravenous (IV) pharmaceuticals was experiencing product leakage issues with its IV bags. The company’s quality and engineering teams identified a solution involving a change to the resin ratio used in the bags to improve strength and eliminate leaks. However, due to unclear FDA guidance documents, the regulatory team was uncertain about the appropriate submission pathway and was preparing a time-consuming Prior Approval Supplement (PAS).

RCA Approach

Regulatory Compliance Associates® Inc. (RCA) was brought in to assess the proposed corrective action and determine the optimal regulatory strategy. RCA’s consultant reviewed the changes and confirmed that the improvement came from adjusting the ratio of existing resins—without introducing any new materials. Based on this analysis, RCA recommended submitting a Changes Being Effected in 30 Days (CBE-30) supplement rather than a PAS, significantly reducing the regulatory timeline.

Result

After consulting with the FDA and confirming agreement with the strategy, the manufacturer submitted a CBE-30. This approach enabled the company to swiftly resolve product complaints, avoid disruptions in supply, and maintain product revenue—without the delays associated with a PAS submission.

21 CFR Part 11 Gap Analysis

Challenge

In preparation for an upcoming FDA audit, a pharmaceutical-grade bulk chemical manufacturer engaged RCA to conduct a comprehensive gap analysis assessing compliance with 21 CFR Part 11 requirements for Electronic Records. RCA was tasked with evaluating eight quality software systems and twenty-nine laboratory software systems to identify gaps and ensure regulatory readiness.

RCA Approach

RCA designed a structured assessment strategy that included targeted interviews with key stakeholders for each software system to evaluate compliance with specific 21 CFR Part 11 requirements. A risk assessment was then conducted to identify high-risk systems based on their level of compliance. Using the results of this analysis, RCA prioritized the software systems and developed a risk-based remediation plan to ensure full regulatory compliance across all platforms.

Result

RCA presented the results of the gap assessment, risk analysis, and system prioritization to the client’s leadership team. Within a month, the FDA conducted an inspection and reviewed the assessment findings along with the remediation plans. Based on the thoroughness and clarity of the approach, the FDA concluded that the client had sufficiently demonstrated progress toward compliance with 21 CFR Part 11—and issued no regulatory observations.

FDA Warning Letter Response and Remediation

Background

A mid-sized company received a 10-item FDA Form 483 and submitted an initial response. However, the response was followed by the issuance of a Warning Letter, leaving the company uncertain about how to effectively engage with the FDA moving forward. The agency had clearly outlined its expectations for the manufacturing of drug and device products at the site, and the management team—having already responded once—was unsure how to construct an appropriate and effective second response.

RCA Approach

Regulatory Compliance Associates® Inc. (RCA) developed a phased program to address both the FDA Warning Letter and broader quality system deficiencies. In Phase I, RCA delivered a detailed response to the Warning Letter, including aggressive timelines and objective evidence demonstrating completed corrective actions. Phase II focused on a comprehensive assessment and remediation of the overall quality system.

RCA created a detailed implementation plan featuring realistic yet ambitious milestones, clearly defined roles and responsibilities, and interdependent task structures to ensure accountability. To lead the initiative, RCA assigned a certified Project Management Professional (PMP), supported by engineers with deep expertise in quality systems and manufacturing engineering, who worked collaboratively with the client’s internal team to drive execution.

Result

The FDA received the Warning Letter responses, timelines, and supporting objective evidence favorably, leading to closure of the Warning Letter within just six months. The best-in-class project management practices applied during Phase II played a critical role in the successful, on-time, and on-budget achievement of key quality system compliance milestones.

Document Management System

Background

Qualitest, a leading manufacturer of high-quality, affordable generic pharmaceuticals, aimed to improve the efficiency of its document change process. At the time, document changes were averaging 50 to 60 days to complete. The company sought to implement a compliant, streamlined process with significantly faster turnaround times.

RCA Approach

Regulatory Compliance Associates® Inc. (RCA) was engaged to assess and enhance the existing document change process. RCA quickly conducted a comprehensive analysis to identify bottlenecks and areas for improvement. In collaboration with Qualitest, RCA revised the applicable standard operating procedures (SOPs) to support a more efficient workflow. Training was conducted for both end users and management, and the new SOPs were piloted to evaluate effectiveness in real-time operations.    

RCA’s wealth of knowledge about our document management system & document control helped us speed up our process, halving the turn-around time.

Result

The pilot was successful and provided valuable feedback for minor refinements. Following the pilot, the improved process was implemented company-wide. As a result, document changes at Qualitest are now completed in under 30 days on average—and often even faster—representing a significant gain in operational efficiency while maintaining full compliance.